Core Viewpoint - Fuyuan Pharmaceutical announced participation in the national organized procurement for drugs, with a procurement period extending until December 31, 2028 [1] Group 1: Company Participation - The company will be involved in the continuation of procurement for five main products, including Eplerenone tablets, Telmisartan tablets, Gliclazide sustained-release tablets, Olmesartan medoxomil tablets, and Repaglinide tablets [1] - Additionally, the company plans to include eight other drugs, such as Venlafaxine hydrochloride sustained-release capsules, in the procurement process [1]

Core Viewpoint - The company has participated in the national organized procurement for drugs whose agreements are expiring, with several drugs expected to be selected in this follow-up procurement [1] Group 1 - The main drugs expected to be selected include Ezetimibe tablets, Telmisartan tablets, Gliclazide sustained-release tablets, Olmesartan medoxomil tablets, and Repaglinide tablets [1]

Group 1: Alzheimer's Disease Market Overview - The global dementia patient population exceeds 55 million, with Alzheimer's disease accounting for approximately 60%-70% of these cases, translating to 33-38.5 million individuals [1] - China has around 10 million Alzheimer's patients, representing about one-third of the global total, with numbers expected to rise due to aging [1] - The economic burden of Alzheimer's disease in China was over 1.2 trillion yuan in 2015, projected to exceed 13 trillion yuan by 2050 [1][2] Group 2: National Action Plan for Dementia - The National Action Plan (2024-2030) aims to implement a health-first strategy to combat dementia, focusing on prevention and treatment [2] - By 2030, the plan seeks to establish a comprehensive dementia prevention and control system, improve early intervention, and enhance care services [2] Group 3: Medical Technology and Innovations - Shenzhen Yiwai Medical Technology Co., Ltd. is recognized as a national-level "little giant" enterprise, specializing in AI for brain disease diagnosis and treatment [3] - The company has developed several innovative products, including the world's first AI medical software for early Alzheimer's diagnosis, which has received both NMPA and CE certifications [3][4] - The AI-assisted diagnostic platform for stroke has also achieved dual certification from NMPA and FDA, marking a significant milestone in the field [4] Group 4: Business Performance and Growth - The subsidiary, Shihe Gene, reported profitability in 2023 and is pursuing an IPO, with a focus on automated NGS solutions for clinical applications [6] - Shihe Gene's products have been recognized globally, with FDA breakthrough device designation for its multi-cancer early screening product [6][7] - The company is expanding its international presence, having established a business network in over 20 countries [6] Group 5: Overseas Market Expansion - The company has successfully achieved overseas sales for its entire line of contrast agents and has received EU GMP and Brazil ANVISA GMP certifications [9] - The expansion into international markets is expected to positively impact the company's operations and revenue growth [9] Group 6: Product Performance and Future Outlook - The contrast agent segment remains a primary revenue source, with stable growth anticipated in 2024 due to successful bidding and international registrations [10] - The company is actively developing new products to enhance its contrast agent pipeline, with recent approvals expected to drive revenue growth [10] - The diabetes medication segment has also seen significant revenue growth, supported by successful bidding processes [11] Group 7: Acquisition Strategy - The company has pursued acquisitions to enhance its competitive position in the contrast agent market and diversify its product offerings [13] - Future acquisitions will align with the company's strategic goals and regulatory requirements [13]